RC48-C009
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- NCT03809013 ↗
- Completed
- RemeGen Co., Ltd.
- Focused
We haven't built an HCP commentary report on RC48-C009 (disitamab vedotin in HER2-overexpressing locally advanced or metastatic urothelial carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RC48-C009 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Urothelial Carcinoma
- Interventions
- RC48-ADC
- Arms
- RC48-ADC · Experimental
- Enrollment
- 64
- Primary outcomes
- Objective Response Rate （ORR）as assessed by the Independent Review Committee
- Sponsor
- RemeGen Co., Ltd.
- Start
- Jan 7, 2019
- Primary completion
- Mar 4, 2021
- Results posted
- No
- Registry record
- NCT03809013 · updated Nov 27, 2023
Publications
linked from the registry- Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, Liu Z, Guo H, Yu G, Ji Z, Ying J, Ling Y, Yu S, Hu Y, Guo J, Fang J, Zhou A, Guo J. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. J Clin Oncol. 2024 Apr 20;42(12):1391-1402. doi: 10.1200/JCO.22.02912. Epub 2023 Nov 21. PubMed 37988648